These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27660505)

  • 1. Acquired Hemophilia A May Be Associated with Ticagrelor Therapy in a 52-Year-Old Man After a Recent Percutaneous Transluminal Coronary Angioplasty.
    Pasquino P; Canaparo R; Capello T; Deorsola B; Perazzolo L; Marengo C; Serpe L
    Clin Med Insights Case Rep; 2016; 9():79-81. PubMed ID: 27660505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A patient with acquired hemophilia A induced by clopidogrel.
    Hwang HW; Kong JH; Yu DW; Kim WT; Kim HS; Lee CI
    Korean J Hematol; 2012 Mar; 47(1):80-2. PubMed ID: 22479283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired hemophilia in the patient suffering from rheumatoid arthritis: case report.
    Drobiecki A; Pasiarski M; Hus I; Sokołowska B; Wątek M
    Blood Coagul Fibrinolysis; 2013 Dec; 24(8):874-80. PubMed ID: 24042266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acquired hemophilia A with high-titer factor VIII inhibitor developing subsequent to clopidogrel administration].
    Shimizu T; Nogami K; Mizutani C; Imada K
    Rinsho Ketsueki; 2019; 60(4):291-295. PubMed ID: 31068558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Systemic lupus erythematosus with acquired hemophilia A: a case report].
    Yang F; Zhou YS; Jia Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Dec; 50(6):1108-1111. PubMed ID: 30562791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
    Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Did Prasugrel and Ticagrelor Offer the Same Benefit in Patients with Acute Coronary Syndromes after Percutaneous Coronary Interventions Compared to Clopidogrel? Insights from Randomized Clinical Trials, Registries and Meta-analysis.
    Rodriguez AE; Rodriguez-Granillo AM; Ascarrunz SD; Peralta-Bazan F; Cho MY
    Curr Pharm Des; 2018; 24(4):465-477. PubMed ID: 29308737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
    Cardiovasc Ther; 2016 Aug; 34(4):209-15. PubMed ID: 27086085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired hemophilia a in a patient with lumbar disc herniation: a case report and review of the literature.
    Li J; Shen H; Hou T; Li M; He S; Zhang H
    Spine (Phila Pa 1976); 2009 Apr; 34(8):E305-8. PubMed ID: 19365240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved ticagrelor antiplatelet effect on discontinuation of phenytoin.
    Weeks P; Sieg A; Vahdat K; Raissi F; Nathan S
    Ann Pharmacother; 2014 May; 48(5):644-7. PubMed ID: 24477376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
    Parker WA; Storey RF
    Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
    Joshi RR; Hossain R; Morton AC; Ecob R; Judge HM; Wales C; Walker JV; Karunakaran A; Storey RF
    Platelets; 2014; 25(6):416-22. PubMed ID: 24111601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Barbieri L; Pergolini P; Verdoia M; Rolla R; Nardin M; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Vascul Pharmacol; 2016 Apr; 79():11-15. PubMed ID: 26518440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention.
    Dane KE; Lindsley JP; Streiff MB; Moliterno AR; Khalid MK; Shanbhag S
    Res Pract Thromb Haemost; 2019 Jul; 3(3):420-423. PubMed ID: 31294330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G
    Expert Opin Pharmacother; 2015; 16(12):1739-47. PubMed ID: 26067422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016.
    Dayoub EJ; Seigerman M; Tuteja S; Kobayashi T; Kolansky DM; Giri J; Groeneveld PW
    JAMA Intern Med; 2018 Jul; 178(7):943-950. PubMed ID: 29799992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Double antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention: individual efficacy and hemorrhagic safety of P2Y12 blockers of ticagrelor and clopidogrel in actual clinical practice].
    Korotaeva ES; Koroleva LY; Kovaleva GV; Kuzmenko EA; Nosov VP
    Kardiologiia; 2019 Jun; 59(5S):27-36. PubMed ID: 31221073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.